Dysregulated cell motility is one of the major characteristics of invasion and metastatic potentials of malignant tumor cells. Here, we examined the hepatocyte growth factor (HGF)-induced cell motility of two human renal carcinoma cell lines, ACHN and VMRC-RCW. Scattering and migration was induced in ACHN in an HGFdependent manner, whereas they were maintained in VMRC-RCW even in the absence of HGF. In VMRC-RCW, HGF receptor (HGFR) tyrosine kinase was constitutively active, and sequence analysis showed N375S, A1209G and V1290L mutations. However, transfection experiments using porcine aortic endothelial (PAE) cells demonstrated that no single mutation or combination of two or three mutations caused HGFindependent constitutive activation. Conversely, the expressed amount of receptor protein had a pivotal role in the basal kinase activity. With respect to downstream signaling molecules of HGFR in ACHN or VMRC-RCW, the Ras-MAPK pathway was downregulated, whereas phosphoinositide 3-kinase (PI3-kinase) was not further activated by HGF-treatment in VMRC-RCW cells. The PI3-kinase inhibitors, wortmannin and LY294002 strongly inhibited spontaneous migration of VMRC-RCW. One transfected PAE cell line with massive overexpression of HGFR demonstrated scattered morphology and increased PI3-kinase activity in association with increased motility, which was partially inhibited by LY294002. Taken together, our results indicate that the overexpression of HGFR causes increase in cellular motility and PI3-kinase shows the important contribution on the increased motility of renal carcinoma cells. Oncogene (2001) 20, 7610 ± 7623.
Introduction
Local invasion and distant metastasis are the major limitations of successful treatment for patients with malignant tumors. The invasive phenotype is characterized by dysregulated cell motility and increased proteolytic activity associated with tumor cells (Levine et al., 1995; Mizejewski, 1999) . Hepatocyte growth factor (HGF) is a pleiotropic growth factor, which was ®rst identi®ed as a mitogen for cultured normal hepatocytes, as a motogen for epithelial cells (scatter factor) and as an epithelial morphogen (Gherardi et al., 1989; Miyazawa et al., 1989; Montesano et al., 1991; Nakamura et al., 1989) . Molecular cloning of these activities showed that a single protein, HGF, caused all cellular responses (see reviews; Bardelli et al., 1997; Birchmeier and Gherardi, 1998; Jeers et al., 1996; Matsumoto and Nakamura, 1997; Zarnegar and Michalopoulos, 1995) . It is now widely known that HGF regulates a number of cellular responses, such as proliferation, migration, survival and morphogenesis of epithelial, endothelial and neuronal cells (Birchmeier and Gherardi, 1998; Jeers et al., 1996) . HGF is produced as a single chain precursor form, proHGF. ProHGF is able to bind to its receptor, HGF receptor (HGFR, also known as c-Met). However, proHGF could not activate HGFR tyrosine kinase (Naka et al., 1992) , suggesting that proteolytic cleavage of proHGF, leading to generation of the heterodimeric active form HGF, is essential for activity (Miyazawa et al., 1993; Naldini et al., 1992) .
HGFR, c-Ron and c-Sea belong to a subfamily of tyrosine kinase receptors, which share structural homology and biochemical features (Comoglio and Boccaccio, 1996; Tamagnone and Comoglio, 1997) . HGFR is composed of a short a-subunit (located outside the membrane) and a long b-subunit (contains an extracellular domain, a transmembrane domain, and a cytoplasmic domain with tyrosine kinase activity). Two doublet tyrosine residues, Y1252 and Y1253 in the kinase domain, are autophosphorylated upon ligand binding and are involved in the increase in the intristic tyrosine kinase activity (Ferracini et al., 1991; Longati et al., 1994) . Y1367 and Y1374 in the C-terminal region of HGFR are also autophosphorylation sites and these residues represent binding sites for multiple signaling molecules containing Src homology 2 (SH2) domains, such as Shc, Grb2, phospholipase C-g, the p85 regulatory subunit of phosphoinositide 3-kinase (PI3-kinase) and Src family kinases . Gab 1, a member of the IRS-1-like multisubstrate binding proteins, can also bind directly to HGFR in an SH2 domain-independent manner (Weidner et al., 1996) . Among these signal transduction molecules, PI3-kinase, the Ras-MAPK pathway, Rac, Rho, Src kinase, SHP-2 and a-diacylglycerol kinase are all implicated in the motility of cultured cells, which are dependent on cell types (Cutrupi et al., 2000; Hartmann et al., 1994; Herrera, 1998; Kodama et al., 2000; Rahimi et al., 1998; Ridley et al., 1995; Royal and Park, 1995; Takaishi et al., 1994; Tanimura et al., 1998) .
Normal renal tubular epithelial cells express HGFR and their growth is tightly regulated by HGF both in vitro and in vivo (Igawa et al., 1991; Kan et al., 1991; Kawaida et al., 1994) . Their transformed phenotype, renal carcinoma cells, also express HGFR (Nakopoulou et al., 1997; Natali et al., 1996) . Recent studies have demonstrated germline or somatic mutations of HGFR in hereditary and sporadic renal cell carcinomas and childhood hepatocellular carcinomas (Park et al., 1999; Schmidt et al., 1997 Schmidt et al., , 1998 Schmidt et al., , 1999 . Many of these mutations have been shown to increase the basal kinase activity of HGFR, so-called constitutive activation, and expression of these mutated receptors was found to be associated with their transforming potential of normal ®broblasts (Jeers et al., 1997) .
In the present study, we used two human cell lines, ACHN cells and VMRC-RCW cells, to examine the role of HGF/HGFR signaling in cellular responses of renal carcinoma cells. VMRC-RCW cells exhibited spontaneous scattered morphology, which was associated with increased motility. The basal kinase activity of the HGFR in these cells was activated in a ligand-independent manner. Sequence analysis revealed three missense mutations. However, transfection experiments demonstrated that none of these mutations was responsible for constitutive activation of HGFR tyrosine kinase, suggesting that these mutations were not responsible for activation of the kinase. Examination of downstream signaling pathways showed that PI3-kinase was not further activated by HGF-treatment in VMRC-RCW cells, and that treatment with PI3-kinase inhibitors wortmannin and LY294002 attenuated the ligand-independent increase in motility. In addition, massive overexpression of HGFR in PAE cells induced scattered morphology in association with increased PI3-kinase and ligand-independent motility, similar to the phenotype of VMRC-RCW cells. Our results indicate that overexpression of HGFR in renal carcinoma cells leads to the increased activity of PI3-kinase, which in turn results in increased motility.
Results

VMRC-RCW cells exhibit increased motility in the absence of HGF
Normal renal tubular epithelial cells express HGFR and their growth and migration are tightly regulated by HGF. Renal carcinoma cells arise from renal tubular epithelial cells and expression of HGFR has also been observed in these cells both in vivo and in vitro (Nakopoulou et al., 1997; Natali et al., 1996) . We ®rst examined the HGF-dependent migration of two human renal carcinoma cell lines, ACHN and VMRC-RCW, using a scatter assay. Figure 1a shows that in the absence of HGF, neighboring ACHN cells contacted each other. HGF treatment of the cells induced scattered morphology, suggesting that scattered morphology was HGF-dependent. In contrast, VMRC-RCW cells exhibited scattered morphology even in the absence of HGF. This morphology could result from either increased motility or loosened cell ± cell contact. To assess these possibilities, polymerized actin bundles were visualized with TRITC-labeled phalloidin. Actin reorganization was observed in ACHN cells in an HGF-dependent manner. However, it was readily observed in the absence of HGF in VMRC-RCW cells (Figure 1b) . These results suggest that the spontaneous scattering in VMRC-RCW cells was associated with increased motility. To quantify the motility of these cells, a chemokinesis assay (undirected migration) was performed. Figure 1c demonstrates that migration of ACHN cells was tightly regulated by HGF and that spontaneous migration was negligible. Conversely, the number of migrated VMRC-RCW cells in the absence of HGF was about sixfold higher than that of ACHN cells. The eect of HGF on migration was also examined and it was found that HGF-dependent motility of VMRC-RCW cells was less than that of ACHN cells. These results indicate the increased motility of VMRC-RCW cells in the absence of HGF.
HGFR is constitutively activated in VMRC-RCW cells
We then examined the HGFR tyrosine kinase activity in VMRC-RCW and ACHN cells. Similar numbers of cells (*6610 6 cells) were serum-starved and either stimulated with 100 ng/ml HGF or left unstimulated for 8 min. HGFR was immunoprecipitated and kinase activity was examined by autophosphorylation of the receptor tyrosine kinase. Figure 2 shows that autophosphorylation of HGFR was ligand-dependent in ACHN cells, whereas strong tyrosine phosphorylation of HGFR was readily observed in untreated VMRC-RCW cells. The expressed amount of HGFR was about 4 ± 5-fold higher in VMRC-RCW cells than in ACHN cells.
Oncogene
Increased motility by HGFR in renal cancer cells T Nakamura et al Constitutive activation of HGFR in VMRC-RCW cells was due to the overexpression of HGFR in association with an autocrine manner Several mechanisms underlie constitutive activation of receptor tyrosine kinases. One mechanism is an autocrine activation. VMRC-RCW cells produce HGF (less than 50 ng/18 h, which was determined by ELISA, data not shown) and HGFR can be activated in an autocrine manner. Cells were cultured in the presence of either non-immune IgG or neutralizing antibody against human HGF. The neutralization Figure 2 Constitutive expression of activated HGF receptor tyrosine kinase in VMRC-RCW cells. Similar numbers of ACHN cells or VMRC-RCW cells were serum-starved and either stimulated with 100 ng/ml HGF or left unstimulated for 8 min. Cells were lysed and HGFR was immunoprecipitated (IP), followed by separation with SDS-polyacrylamide gel electrophoresis. After transfer of proteins onto PVDF membranes, immunoblot analyses (IB) were performed with either anti-phosphotyrosine (4G10) or anti-HGFR antibody. The HGFR b-chain and precursor form of HGFR are indicated as HGFRb and HGFR prec., respectively. Representative results were obtained from three independent experiments ability was determined by incubation of recombinant HGF with antibody followed by scattering of MDCK cells. Scattering of MDCK cells by 20 ng HGF was almost completely inhibited by 40 mg of antibody. VMRC-RCW cells (6610 6 cells) were then incubated overnight with 200 mg of either the antibody or nonimmune goat IgG in serum-free conditions. Cells were washed and fresh serum-free medium without antibody was added. Cells were immediately stimulated with 100 ng/ml HGF or left unstimulated for 8 min and lysed. Figure 3a shows that treatment with anti-HGF antibody mildly decreased tyrosine phosphorylation of non-stimulated HGFR, but not the HGF-stimulated receptor. This result indicates that the constitutive activation involves an autocrine mechanism.
A genomic rearrangement that generates a hybrid protein containing a Tpr sequence at its amino terminus fused directly to the HGFR tyrosine kinase domain, was shown to cause constitutive activation (Cooper et al., 1984; Park et al., 1986) . However, this was not the case in our study as the molecular weight of Tpr-Met was 65 kDa and a tyrosine phosphorylated band of 65 kDa was never observed. Another possible mechanism underlying constitutive activation of HGFR is Figure 3 (a) Increased basal HGFR tyrosine kinase activity in VMRC-RCW in an autocrine manner. Cells were cultured in the presence of either anti-human HGF goat IgG or non-immune goat IgG. Cells were washed and fresh serum-free medium without anti-HGF antibody was added, and the cells were then immediately stimulated with 100 ng/ml HGF or left unstimulated. Autophosphorylation of HGFR was examined by immunoprecipitation (IP) followed by immunoblotting (IB). Relative phosphorylation was estimated by the ratio of the density of phosphotyrosine band/corresponding receptor band. (b) None of the stable PAE cell lines expressing combinations of two or three mutations of HGFR found in VMRC-RCW cells resulted in constitutive activation. Cell lines expressing similar amounts of mutant receptors were serum-starved and either stimulated with HGF or left unstimulated, followed by immunoprecipitation (IP) and immunoblotting (IB). (c) Expressed amount of receptor protein aects basal kinase activity. PAE cells expressing distinct amounts of receptor protein were serum-starved and lysed. Basal kinase activity was examined by immunoblotting. Representative data were obtained from two independent experiments missense mutation of the gene encoding HGFR.
Complementary DNA encoding HGFR of VMRC-RCW cells was isolated and sequence analysis showed three missense mutations. Adenine at 1318 was mutated to guanine, cytosine at 3820 to guanine in association with guanine at 3821 to cytosine, and guanine at 4062 to cytosine, leading to N375S (in the extracellular region), A1209G and V1290L mutations (both in the kinase domain), respectively. These mutations have not been reported previously. Using site-directed mutagenesis, mutations were corrected and cDNAs constructed which encoded wild type and mutated receptors. Each single mutation and two combined mutations were subcloned into the pcDNA3.1 mammalian expression plasmid. Expression plasmids were introduced into PAE cells with the FuGene 6 transfection reagent and transfectants screened for G418-resistant clones. PAE cells were selected for this study as their HGFR expression was below detectable levels, suggesting that these cells would be a useful model for determination of basal kinase activity of transfected HGFR and have intact signaling pathways downstream of HGFR. Expression of HGFR and HGFR tyrosine kinase activity was examined by immunoblotting. However, no single mutation caused an increase in the basal kinase activity of transfected HGFR (data not shown). Paca 2 cells also express very small amount of endogenous HGFR. Paca 2 cells were also transfected with expression plasmid containing HGFR of either wild type or with each single mutation. However, no stable Paca 2 cell lines demonstrated increase in basal kinase activity of HGFR (data not shown). We therefore examined the eect of combined mutations of HGFR in its basal kinase activity by using PAE cells. Figure 3b demonstrates that each combination of two mutations and the original mutant receptor (from VMRC-RCW cells) exhibited low basal kinase activity and HGF treatment clearly increased their kinase activities to a similar extent. These results suggest that the mutations found in HGFR from VMRC-RCW cells are not responsible for constitutive activation.
We then examined the eect of the amount of receptor protein expressed on basal kinase activity. Three stable cell lines expressing wild type receptor (WT-3, -5 and -10 cells, respectively) were obtained. Equal numbers of cells were serum-starved for 2 h and HGFR was immunoprecipitated followed by immunoblotting. Figure 3c shows that the level of expression actually aected the basal autophosphorylation of HGFR tyrosine kinase. Similar results were observed in cell lines expressing mutant HGFR. Summarizing these data, we conclude that HGFR overexpression and to a lesser extent, an autocrine mechanism, induce constitutive activation of HGFR in VMRC-RCW cells.
The Ras/MAPK pathway is downregulated whereas P13-kinase is upregulated downstream of HGFR in VMRC-RCW cells
To examine the downstream signal transduction pathways associated with HGFR, cells were either stimulated with 100 ng/ml HGF or left unstimulated for 8 min and then lysed. Shc, an adaptor protein upstream of Ras, was immunoprecipitated and tyrosine phosphorylation was examined. Figure 4a shows that tyrosine phosphorylation of Shc was increased by HGF treatment in ACHN cells, but no increase was observed in VMRC-RCW cells. Association of Shc with Grb2, another adaptor protein upstream of Ras, was increased by HGF in ACHN cells, but not in VMRC-RCW cells. The kinetics of MAPK activation were examined using total cellular extracts. MAPK was strongly activated by HGF in ACHN cells and sustained activation was clearly observed at 120 min after stimulation (Figure 4b ). In VMRC-RCW cells, MAPK activation was weak and sustained activation was barely evident. These data suggest that the Ras-MAPK pathway downstream of HGFR is downregulated in VMRC-RCW cells.
The EGF receptor (EGFR) was also expressed in these cells. Autophosphorylation of EGFR was liganddependent in both cell types, suggesting that EGFR expression was not constitutively active in these cells (Figure 5a ). Constitutive activation of the insulin receptor in NIH3T3 cells causes unresponsiveness of MAPK activation by insulin, EGF and platelet-derived growth factor (Antonyak et al., 1998) . To examine the eect of constitutively active HGFR on downstream signaling molecules of EGFR, we investigated the Ras-MAPK pathway. In these cells, tyrosine phosphorylation of Shc and association with Grb2 were EGFdependent (Figure 5b ). The increase in tyrosine phosphorylation of Shc and association with Grb2 were somewhat less in VMRC-RCW cells than in ACHN cells. This may be due to expression of constitutively active HGFR. EGF-dependent MAPK activation was examined and sustained activation was observed in VMRC-RCW cells and ACHN cells (Figure 5c ). These results suggest that the Ras-MAPK pathway can be activated by EGF in VMRC-RCW cells. PI3-kinase activity was then examined in antiphosphotyrosine immunoprecipitates of these cells. PI3-kinase was activated by HGF and EGF treatment in ACHN cells (Figure 6 ). In VMRC-RCW cells, PI3-kinase was not further activated by HGF and EGF treatment and the PI3-kinase inhibitors, wortmannin and LY294002, strongly inhibited this activation. It is therefore possible that PI3-kinase is chronically activated in VMRC-RCW cells.
Examination of downstream signal transduction pathways in HGFR-transfected PAE cells
We then investigated the Ras/MAPK pathway in PAE cells expressing wild type HGFR (WT-3, -5 and -10). Shc was immunoprecipitated from lysates of equal numbers of cells and ligand-dependent tyrosine phosphorylation was assayed. In empty vector-transfected cells (Mock), Shc was tyrosine-phosphorylated, suggesting that PAE cells expressed HGFR endogenously below detectable levels. Tyrosine phosphorylaIncreased motility by HGFR in renal cancer cells T Nakamura et al tion of Shc and association with Grb2 were similar in each cell line, and activation of MAPK was also observed to a similar degree (Figure 7a,b) . These results indicate that basal kinase activity does not aect the Ras/MAPK pathway. In contrast, basal PI3-kinase activity in immunoprecipitates of anti-phosphotyrosine increased in parallel to the basal tyrosine phosphorylation level of HGFR (Figure 7c ). The amount of p85 regulatory subunit was the same in these cells ( Figure  7d ), suggesting that basal kinase activity is important for the PI3-kinase activation through association of p85 with phosphotyrosine proteins, such as HGFR and Gab 1. During the establishment and examination of stable cell lines expressing either wild type or mutant HGFR, we isolated a cell line with massive overexpression of HGFR protein levels, which had both N375S and V1290L mutations, denoted mut. 1, 3 -2 cells. As shown in Figure 3b , these mutations caused no structurally-related activation of HGFR tyrosine kinase. In addition, this cell line did not produce detectable levels of HGF protein (data not shown). Interestingly, the cells exhibited scattered morphology as has been observed in VMRC-RCW cells (Figure 8a ). Motility and signaling pathways via HGFR were examined in comparison with WT-10 PAE cells. Tyrosine phosphorylation of the transfected receptor in mut. 1, 3 -2 cells exhibited almost no liganddependence, which was similar to that in VMRC-RCW cells (Figure 8b ). Basal PI3-kinase activity was higher in mut. 1, 3 -2 cells than in WT-10 cells, whereas the increase in its activity induced by HGF treatment was greater in WT-10 cells than in mut. 1, 3 -2 cells ( Figure  8c ). These results indicate that PI3-kinase activation is more sensitive to HGF in WT-10 cells than mut. 1, 3 -2 cells. Ras/MAPK activation was HGF-dependent in these cells, indicating that overexpression and constitutive activation of HGFR itself has no remarkable eect on the Ras/MAPK pathway in PAE cells (Figure  8d,e) .
Finally, we investigated the signal transduction pathways via HGFR leading to migration of renal carcinoma cells. The MEK inhibitor PD98059 had little eect on HGF-induced chemokinesis of ACHN cells (Figure 9a ). The PI3-kinase inhibitors wortmannin and LY294002 strongly inhibited HGF-induced chemokinesis by ACHN cells. These results suggest that PI3-kinase activation via HGFR plays pivotal roles in HGF-induced migration of renal carcinoma cells, as mentioned above. In VMRC-RCW cells, PI3-kinase was constitutively activated and the Ras-MAPK pathway was downregulated. To examine the role of PI3-kinase activity in HGF-independent migration, cells were treated with either wortmannin, LY294002, or PD98059 and HGF-independent chemokinesis was examined. Figure 9b shows that both wortmannin and LY294002 strongly inhibited chemokinesis, whereas PD98059 did not. These results indicate that chronically activated PI3-kinase is implicated in the increased motility of VMRC-RCW cells. We also examined chemokinesis of PAE cells overexpressing HGFR. Figure 10a shows that mut. 1, 3 -2 cells exhibited increased HGF-independent motility whereas almost no increase was observed following HGF treatment. Conversely, motility of WT-10 cells was clearly HGF-dependent. Examination of the eect of LY294002 on motility of mut. 1, 3 -2 cells in the absence of HGF (Figure 10b) showed that LY294002 inhibited about 55% of basal migration, indicating that PI3-kinase activity contributes, at least in part, to the increased motility.
Discussion
The major ®nding of the present study is the constitutive activation of HGFR tyrosine kinase in renal carcinoma cells (VMRC-RCW) is associated with increased motility. Motility of VMRC-RCW cells could be further stimulated by HGF-treatment, whereas PI3-kinase in these cells was not. PI3-kinase inhibitor strongly, but not completely attenuated the increased motility of VMRC-RCW, suggesting that HGFR-activated PI3-kinase was at least partially involved in increased motility. In addition, similar phenotype was genetically created by massive overexpression of HGFR in PAE cells. Downstream of activated HGFR, Ras/MAPK pathway was varied between VMRC-RCW cells and PAE cells. However, PI3-kinase was similarly elevated in these cells via activated HGFR.
Several mechanisms underlie constitutive activation of receptor tyrosine kinases. One of these is autocrine stimulation resulting in autophosphorylation of receptors (Huang and Huang, 1988; Keating and Williams, 1988) . In the present study, autocrine stimulation contributed to constitutive activation of HGFR in VMRC-RCW cells. Overexpression of receptor proteins can also be responsible for basal kinase activation (Rusciano et al., 1996) . Our data were inconsistent with this mechanism (Figures 3c and 8b) . Genomic rearrangements that juxtapose novel sequences derived , 1994) . However, we could not detect active kinase proteins of smaller molecular weights. Recently, activating missense mutations of receptor tyrosine kinases have been reported (see review, Robertson et al., 2000) . Mutation of amino acids to cysteine in the extracellular domain of a receptor tyrosine kinase causes formation of a disul®de bridge between cysteines of two receptor molecules, facilitating ligand-independent dimerization and activation. Ret or ®broblast growth factor receptors are activated by this type of mutation, resulting in multiple endocrine neoplasia type 2A and chondroskeletal disorders, respectively (Chappuis-Flament et al., 1998; Neilson and Friesel, 1996) . Mutations in the transmembrane region of ®broblast growth factor receptor 3 (G380R) and Neu (V664E) also result in constitutive activation (Webster and Donoghue, 1996; Weiner et al., 1989) . The mechanism of this activation is also a ligand-independent dimerization or stabilization of two receptor molecules. It has been postulated that dimerization involves participation of hydrogen-bond formation through either N-H or O-H groups in these side chains (Webster and Donoghue, 1996) . Mutations have been also detected in kinase domains of receptor tyrosine kinases. Activation of receptor tyrosine kinases requires tyrosine phosphorylation in the activation loop of the kinase domain, followed by conformational change of this loop to open the ATPbinding pocket (Hubbard et al., 1998) . Based on the crystal structure of the insulin receptor (Hubbard et al., 1994) , a 3-D model of the HGFR kinase domain was constructed by Schmidt et al. (1999) . According to this model, access to ATP and substrate binding was blocked by the activating loop. Mutations in the activating loop of the kinase domain may change and stabilize the binding site of the activation loop to another site, which in turn allows the association of ATP with the adenine-binding pocket. It is also possible that conformational changes of tyrosine kinase domains and the activation loop may cause destabilization of the activation loop. In a series of sequence analyses reported previously, all activating mutations were located in the kinase domain (Park et al., 1999; Schmidt et al., 1997 Schmidt et al., , 1998 Schmidt et al., , 1999 . Almost all mutations were close to the entrance of the adenine-binding pocket or in the activation loop (Schmidt et al., 1999) . In addition, many mutations found in the series of HGFR were substitutions of amino acid residues to those belonging to a dierent group. For instance, the M1268T mutation, which is a mutation conserved in Ret MEN2B, converts a hydrophobic to a neutral amino acid. Y1248H and D1246H (conserved in c-Kit causing mastocytosis, Nagata et al., 1995; Piao and Bernstein, 1996) demonstrate substitutions from acidic to basic amino acids. These mutations possibly change the conformation of the kinase domain in such a way that increases its kinase activation. According to the proposed 3-D model (Schmidt et al., 1999) , the V1290L mutation was present in the second lobe of the kinase domain and was distant from the entrance of the adenine-binding pocket. A1209G may be a natural variant, as the HGFR sequence in GenBank (accession number X54559) encoded G1209A and comparison with other tyrosine kinases, such as c-ErbB, c-Src, c-Kit, and c-Ret all demonstrated this conserved residue as a G. In addition, A to G mutation is a transition within the same hydrophobic group. N375S was present in the extracellular domain. However, this mutation was also a transition within the same neutral hydrophilic group. It is dicult to speculate on the conformational change caused by this mutation, and serine residues involved in dimerization and stabilization of two receptor molecules has never been reported. Taking all these data into consideration, mutations detected in this study do not appear capable of causing constitutive activation.
It has been demonstrated that the tyrosine kinase activity of an activating mutant HGFR was still Representative results were obtained from three independent experiments stimulated by the ligand (Michieli et al., 1999) . This ®nding suggests that two classes of activating mutations are present. Mutations of amino acids in the extracellular or transmembrane domain may cause ligand-independent dimerization of receptor molecules. Conversely, mutations found in the intracellular domain may be further stimulated by ligands. It is therefore important to assess ligand-dependency by using stable transfected cell lines expressing a variety of receptor proteins. If ligand-dependency is intact, the levels of ligand expressed during development and aging may modulate diseases caused by the mutant receptor. The eect of receptor density on activity of receptor tyrosine kinases should also be examined. The amount of HGFR expressed was highly sensitive to its basal kinase activity in transfected PAE cells. It is possible that receptor tyrosine kinases that have an activating mutation may be sensitive to HGFR expression levels. To exclude this possibility, kinase activity should be determined using stable cell lines expressing dierent levels of receptor proteins.
Constitutive activation of receptor tyrosine kinases is frequently associated with malignant tumors. However, it is not clear whether mutation of receptor tyrosine kinases simply causes malignant transformation of normal cells. Receptor tyrosine kinases activate a number of downstream signaling cascades, such as the Ras/MAPK pathway and PI3-kinase (Hanks et al., 1988; Pawson and Scott, 1997; Weiss and Schlessinger, 1998) . It is therefore important to examine the relationship between downstream signaling molecules and cellular responses. Several studies have demonstrated the eects of constitutive activation of growth factor receptor tyrosine kinases on downstream signal transduction pathways. The amino-truncated variant form of EGFR, denoted EGFRvIII, is constitutively active and is found in human brain, breast, lung and ovarian tumors (Voldborg et al., 1997) . Downstream of this receptor, the Ras-MAPK pathway was downregulated (Moscatello et al., 1996) , and PI3-kinase and c-Jun N-terminal kinase were chronically activated (Inoue et al., 1996; Moscatello et al., 1998) in NIH3T3 cells. Constitutive activation of the insulin receptor in NIH3T3 cells induced constitutive activation of PI3-kinase and unresponsiveness of MAPK activation by insulin, EGF, and platelet-derived growth factor (Antonyak et al., 1998) .
According to our data, the Ras-MAPK pathway was downregulated and PI3-kinase was chronically active downstream of HGFR. However, the Ras-MAPK Figure 7 Basal kinase activity of wild type HGFR transfected into PAE cells aected PI3-kinase activity, but not the Ras/MAPK pathway. PAE cells used in Figure 3c were either stimulated with HGF or left unstimulated, and 90% of the lysates used for immunoprecipitation with anti-Shc antibody (a) and the remaining 10% lysates used as total cell extracts (b). Proteins were separated by SDS ± PAGE and immunoblot analyses were performed using the indicated antibody. Similarly, 90% of lysate was immunoprecipitated with anti-phosphotyrosine, followed by in vitro PI3-kinase assay (c). The remaining 10% of lysate was electrophoresed, followed by immunoblotting with anti-p85 antibody (d). Representative data were obtained from two independent experiments Increased motility by HGFR in renal cancer cells T Nakamura et al . Cells were treated with 0.1% DMSO, 50 mM PD98059, 100 nM wortmannin, or 50 mM LY294002 for 30 min and inoculated onto collagen-coated membranes of Transwell 1 in the presence or absence of indicated inhibitors with or without 100 ng/ml HGF as described in the legend of Figure 1c . Cells that migrated onto the lower surface were counted. Values were expressed as mean+s.d. of quadruplicate wells. Representative data were obtained from two independent experiments pathway remained responsive to EGF treatment in VMRC-RCW cells, and PAE cells remarkably overexpressing HGFR protein exhibited no dierence in HGF-dependent activation of the Ras/MAPK pathway. In addition, MAPK was shown to be chronically activated downstream of a constitutively active prolactin receptor in 32Dc13 cells . The prolactin receptor is a class of cytokine receptor family, which lacks a tyrosine kinase domain. Cytokine receptors activate two classes of tyrosine kinases, the Janus family of tyrosine kinases and the Src family kinases, instead of receptor tyrosine kinase. These data suggest that constitutive activation of receptor tyrosine kinase does not universally result in attenuated Ras/ MAPK activation.
Conversely, PI3-kinase activity appears to be increased downstream of elevated receptor tyrosine kinase expression. Regulation of PI3-kinase activity is rather complex (Fruman et al., 1998; Stein and Water®eld, 2000; Wymann and Pirola, 1998 ). However, two major mechanisms are involved. One mechanism is the binding of the p85 regulatory subunit of PI3-kinase to tyrosine-phosphorylated proteins. The binding of p85 to phosphotyrosine-containing peptides increases the catalytic activity p110 subunit (Holt et al., 1994; Klippel et al., 1992) . Another mechanism is the activation of p110 catalytic subunit by GTP-loaded Ras. Previous reports comparing PI3-kinase activation by ®broblast growth factor (FGF)-2 and plateletderived growth factor (PDGF) have shown that PDGF-induced PI3-kinase activation utilized two mechanisms, whereas FGF-2-induced activation lacked the association of the p85 subunit to phosphotyrosinecontaining proteins resulting in extremely weak activation (Kanda et al., 1997; van Weering et al., 1998) . It is therefore possible that tyrosine-phosphorylated proteins increased in the downstream of activated receptor tyrosine kinase, which in turn led to binding of p85 to these proteins and an increase in its catalytic activity.
One PAE cell line with massive overexpression of HGFR (mut. 1, 3 -2 cells) exhibited strong basal kinase activity, scattered morphology, increased PI3-kinase activity and increased motility. The PI3-kinase inhibitor LY294002 partially inhibited the increased motility of this PAE cell line, suggesting that increased PI3-kinase contributed to the increase in motility. These results indicate that the increase in motility and PI3-kinase activity is due to the high basal kinase activity of HGFR. The partial inhibition of mut. 1, 3 -2 cells may be due to involvement of other signaling pathways, such as Src kinase and a-diacylglycerol kinase. This is the ®rst demonstration that overexpression of receptor tyrosine kinase itself induces similar characteristics in dierent types of cells.
Dysregulation of cell motility may be involved in tumor invasion and metastasis in vivo. However, there are few suitable models for evaluating the role of increased motility in tumor invasion and metastasis in vivo (Wells, 2000) . Expression of mutant HGFR and wild type receptor in the same tumor cells, which have the same genetic background, may therefore become a useful tool for investigation of the biological roles of activating mutations of growth factor receptors in tumor progression in vivo.
Materials and methods
Antibodies and pharmacological inhibitors
Anti-phosphotyrosine monoclonal antibody (4G10) and antiErk 1/2 (C-terminal) antibody were obtained from Upstate Biotechnologies, Inc. (Lake Placid, NY, USA). Antiphosphorylated (activated) MAPK polyclonal antibody and MEK inhibitor, PD98059 were purchased from New England BioLabs (Beverly, MA, USA) and anti-human HGFR polyclonal antibody, anti-EGFR antibody, and anti-Erk 2 antibody were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies against Grb2 and Shc, and antiphosphotyrosine PY20 monoclonal antibody were obtained from Transduction Laboratories, Inc. (Lexington, KY, USA). PI3-kinase inhibitors, wortmannin and LY294002 were from Calbiochem-Novabiochem Corp. (San Diego, CA, USA). PD98059, wortmannin, and LY294002 were dissolved in dimethyl sulfoxide (DMSO) at high concentrations and stored at 7308C. Just prior to use, inhibitors were diluted with DMSO and further diluted 1000 times with culture medium, which resulted in a ®nal concentration of DMSO in the culture medium of 0.1%.
Cell culture
Human renal carcinoma cells, denoted ACHN cells and VMRC-RCW cells (Nishimura et al., 1992) , were maintained 
Scatter assay
The scatter assay was performed by the method described previously (Medico et al., 1996) . In brief, cells were inoculated into wells of 6-well plates at a density of 3610 4 cells/well in the presence of 10% FBS and cultured for 24 h. The medium was replaced with serum-free medium in the presence or absence of 50 ng/ml recombinant human HGF (R&D Systems, Minneapolis, MN, USA) and the culture was continued for 24 h. Photographs were taken under phasecontrast microscopy.
Determination of actin polymerization
Cells were grown on cover slips and incubated with serumfree medium for 16 h. Cells were either stimulated with 50 ng/ml HGF or left unstimulated for 15 min and then washed with 20 mM Tris-HCl, pH 7.5, containing 150 mM NaCl (TBS). Cells were ®xed with 3.5% paraformaldehyde in phosphate-buered saline for 20 min at room temperature, followed by incubation with 0.1% Triton X-100 in TBS for 3 min. Cells were washed with TBS and incubated with TRITC-conjugated phalloidin (Sigma Chemical Company, St. Louis, MO, USA) for 40 min. After washing and mounting, photographs were taken under¯uorescence microscopy.
Chemokinesis assay
The chemokinesis assay was performed by the method described elsewhere with some modi®cations (Kanda et al., 2000) . In brief, membranes of inserts of Transwell 1 (#3422; Corning Incorporated, Corning, NY, USA) were coated with type I collagen from rat tail tendon (Nitta Gelatin, Osaka, Japan). Cells were either treated with 0.1% DMSO, 100 nM wortmannin, 50 mM LY294002, or 50 mM PD98059 for 30 min, or left untreated. Cells were suspended in serum-free MEM supplemented with 0.25% BSA for renal carcinoma cells. Because of the high-dependency of the serum, the chemokinesis assay of PAE cells was determined in the presence of 10% serum as reported previously (Wennstrom et al., 1994) . In indicated wells, cells were suspended in medium supplemented with 0.1% DMSO, inhibitors and/or HGF and seeded onto the upper surface of the membranes of inserts. Lower chambers were ®lled with the same medium and supplements as those of cell suspensions. After 24 h, cells were ®xed and stained with Giemsa solution. After wiping the upper surface of the stained membranes with a cotton swab to remove non-migrating cells, all cells present on the lower surface of the membranes were counted microscopically.
Oligonucleotides and probes
Probes to screen a cDNA library by low stringency hybridization were obtained by polymerase chain reaction (PCR) using degenerate oligonucleotide primers and cDNA from VMRC-RCW cells as a template. The primers were synthesized based on the human c-Met (GenBank accession number; J02958) by Sawady Technologies, Inc. (Tokyo, Japan). Ampli®ed fragments were subcloned into a TAcloning vector (Invitrogen, San Diego, CA, USA). The inserts obtained by digestion with EcoRI were 32 P-labeled with the Megaprime DNA labeling system (Amersham Pharmacia Biotech) according to the instructions provided by the manufacturer.
Cloning and sequence analysis of cDNA encoding HGFR of VMRC-RCW cells Total RNA was extracted from cultured VMRC-RCW cells using ISOGEN (Nippon Gene, Tokyo, Japan) and mRNA was puri®ed. cDNA was synthesized and a library was constructed with the Lambda ZAP II Predigested EcoRI/ CIAP-Treated Kit (Stratagene, La Jolla, CA, USA) according to the instructions provided by the manufacturer. cDNA was ampli®ed in XL1-Blue Escherichia coli and the ®rst screening was performed with duplicate membranes with Nterminal and C-terminal probes, respectively, and positive plaques hybridized with both probes were further examined for the secondary screening. Finally, four positive clones were obtained, and the cDNA inserts were excised from the phage vector as a plasmid form. Sequencing of cloned HGFR from VMRC-RCW cells was performed using a dye-terminator sequencing method with appropriate internal primers according to the instructions provided by the manufacturer (ABI PRISM 377, Perkin Elmer-Cetus, Foster City, CA, USA). Nucleotides were numbered according to the scheme in GenBank Accession number J02958.
Site-directed mutagenesis
Based on the human sequence of HGFR, cDNAs in pBlueScript SK (7) vector for wild type, N375S, A1209G, V1290L, N375S+A1209G, N374S+V1290L, and A1209G+V1290L HGFRs were constructed with the QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to the protocol provided by the manufacturer. The mutated region of cDNA was subcloned into the pcDNA3.1 mammalian expression plasmid (Invitrogen), together with the other region of HGFR cDNA from VMRC-RCW cells. Sequences of all constructs were con®rmed by sequencing.
Establishment of stable cell lines expressing wild type or mutant HGFRs
PAE cells were incubated with FuGene6 transfection reagent (Roche Diagnostics) premixed with 3 mg each of expression plasmid containing cDNA encoding either wild type or mutant HGFR constructs. After 48 h, cells were incubated with Ham's F-12 medium supplemented with 10% FBS and 0.4 mg/ml G418, and then 12 to 24 resistant clones from each transfectant were isolated and screened for the expression of transfected HGFR by immunoprecipitation followed by immunoblotting as described below.
Immunoprecipitation and immunoblotting
Immunoprecipitation followed by immunoblotting was performed by the methods described previously by our laboratory (Kanda et al., 2000) . Brie¯y, renal carcinoma cells were serum-starved overnight and stimulated with 100 ng/ml HGF or EGF or left unstimulated for indicated periods. PAE cells were serum-starved for 2 h prior to the experiments. Cells were rinsed and lysed in Nonidet P-40 lysis buer and cleared lysate was incubated with indicated antibodies on ice, followed by precipitation with protein Aagarose beads. For determination of activated MAPK, total cell lysates were prepared by lysing cells in boiled SDSsample buer. Proteins were applied onto SDS-polyacrylamide gels and separated, and then transferred onto PVDF membranes (Millipore, Bedford, MA, USA). Membranes were incubated with indicated antibodies, followed by incubation with peroxidase-conjugated secondary antibodies. Proteins were visualized using enhanced chemiluminescence reagents (Amersham) and exposed on X-ray ®lms. Between two probings, the membranes were stripped as described (Kanda et al., 2000) . In indicated blots, the density of particular bands was measured by Densito-pattern analyzer, model EPA-3000 (Chemiway/Maruzen Petrochemical Co., Tokyo, Japan) and the relative tyrosine phosphorylation of the immunoprecipitated proteins was calculated by the ratio of optimal density in anti-phosphotyrosine blot/optimal density in recovered protein.
PI3-kinase assay
An in vitro PI3-kinase assay was performed as described previously (Kanda et al., 1997) . In brief, cells were stimulated with 100 ng/ml HGF or EGF or left unstimulated in the presence of 0.1 mM orthovanadate for 5 min. After washing, cells were lysed in NP-40 lysis buer and clari®ed lysate was incubated with anti-phosphotyrosine monoclonal antibody followed by adsorption with protein A-agarose beads. Beads were washed and incubated with phosphatidylinositol in the presence of [g-32 P]ATP for 10 min at room temperature. The reaction was stopped and the reaction products were resolved by thin layer chromatography on silica Gel-60 plates. Radioactivity in each spot was measured using a BioImaging Analyzer BAS-5000 (Fuji) and then exposed on X-ray ®lms. Relative activity obtained from unstimulated cells was set as 1.
